Salama, April K.

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2015) · New England Journal of Medicine

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 2,781

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial

Hodi, F. S., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K. F., McDermott, D. F., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2016) · The Lancet Oncology

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 968

Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma

Nathan, P., Hassel, J. C., Rutkowski, P., Baurain, J.-F., Butler, M. O., Schlaak, M., Sullivan, R. J., Ochsenreither, S., Dummer, R., Kirkwood, J. M., et al. (2021) · New England Journal of Medicine

Ocular Oncology and TreatmentsOcular Diseases and Behçet’s Syndrome

Cited by 924

Irradiation and immunotherapy: From concept to the clinic

Salama, A. K. S., Postow, M. A., & Salama, J. K. (2016) · Cancer

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 85

Checkpoint inhibitor use in two heart transplant patients with metastatic melanoma and review of high-risk populations

Grant, M. J., DeVito, N., & Salama, A. K. S. (2018) · Melanoma Management

Cancer Immunotherapy and BiomarkersTransplantation: Methods and Outcomes

Cited by 24